FDA Warns Imprimis for False and Misleading Website and Twitter Promotions
By Zachary Brennan -
Published 16 January 2018
The US Food and Drug Administration (FDA) late last month sent a warning letter to San Diego-based Imprimis Pharmaceuticals for false and misleading claims made on the company’s website and Twitter account, among other violations.
Categories: News, US, FDA, Advertising and Promotion, Compliance, Drugs, Government affairs, Manufacturing
Tags: Imprimis, Twitter, FDA warning letters